Douglas Palmer

Douglas Palmer is currently the Executive Director of Immuno-Oncology Translational Medicine at AstraZeneca, where they provide strategic leadership to enhance immunotherapy research and development. With two decades of experience at the National Cancer Institute, they co-authored over 63 manuscripts and led pioneering research that resulted in one of the first CRISPR gene editing clinical trials in the U.S. They hold a PhD in Immunology from The George Washington University and have been recognized with numerous commendations for their contributions to the field.